コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 s, which are specific mutations in the Wilms tumor gene.
2 the product of the lethal(3)malignant brain tumor gene.
3 indicated that these sites may harbor Wilms tumor genes.
4 identify novel activities for existing anti-tumor genes.
5 ty, and immunogenicity of a polyvalent Wilms tumor gene 1 (WT1) peptide vaccine in patients with acut
7 emonstrate increased expression of the Wilms tumor gene 1 product (WT1), making WT1 an attractive the
9 e that PPP2R1A is not the 19q familial Wilms tumor gene and that mutation of PPP2R1A is not a common
10 wn to be overexpressed in AML such as Wilms' tumor gene, and multiparameter flow cytometry to detect
11 The OrCGDB is part of a larger WWW-based tumor gene database and represents a new approach to cat
12 structured digital publication software; the Tumor Gene Database, containing information about genes
13 to assess potential synergy of combined anti-tumor gene delivery and to identify novel activities for
17 ermine the relationship between quantitative tumor gene expression and risk of cancer recurrence in p
19 changes) alter tumor biology as assessed by tumor gene expression changes, with a common mechanism p
20 approach based upon statistical analysis of tumor gene expression data combined with experimental va
21 ncer cell lines and applying these models to tumor gene expression data in the clinical data sets (e.
24 e of absolute cell fraction predictions from tumor gene expression data, and provides a unique novel
29 rrying out a meta-analysis of primary breast tumor gene expression from 1,378 early-stage breast canc
32 tability leading to mammary tumors that have tumor gene expression profiles closely resembling mature
33 be coexpressed with VEGFR-2 from a clinical tumor gene expression profiling database and between tum
37 ides an exciting new technology for relating tumor gene expression to patient outcome, but it also pr
38 possibility of pharmacologically modulating tumor gene expression to result in targeted radiotherapy
39 r predicts subtype and patient survival than tumor gene expression, and genes with coordinated expres
40 l loci methylation inversely correlated with tumor gene expression, most notably KCNH2 (HERG, a potas
42 accounted for 1.2% of the total variation of tumor gene expression, while somatic copy-number alterat
43 o integrated RNA-Seq data in various primary tumors, gene expression microarray data in over 1000 can
44 d constitutional epigenetic defects in Wilms tumor genes extend the understanding of Wilms tumor risk
46 ighly similar between responding ILC and IDC tumors; genes involved in proliferation were downregulat
51 the negative regulatory domain of the Wilms' tumor gene product (WT1) in a yeast two-hybrid screen an
52 In this study, we report that the Wilms' tumor gene product WT1, a zinc finger transcription fact
57 ese findings have important implications for tumor gene therapy and for understanding the mechanism o
62 tic interactions between cut and the ovarian tumor gene were identified as a result of the screen.
63 elopment requires the functions of the Wilms tumor gene WT1 and the WNT/beta-catenin signaling pathwa
66 view recent findings showing that the Wilms' tumor gene (Wt1) is a key regulator of mesenchyme mainte
70 ed targets and regulators of the first Wilms tumor gene, WT1, has uncovered several candidate genes a
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。